Type 1 Diabetes vs Type 2 Diabetes — Clinical Trial Comparison
Type 1 Diabetes
Autoimmune beta-cell destruction
VS
Type 2 Diabetes
Insulin resistance and progressive beta-cell decline
Type 1 and type 2 diabetes are fundamentally different diseases that share high blood glucose as a common feature. Their clinical trial landscapes are equally distinct — type 1 trials focus on immune modulation, beta-cell preservation, and technology, while type 2 trials test an expanding range of drug classes and metabolic targets.
Key Differences at a Glance
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Cause | Autoimmune destruction of pancreatic beta cells | Insulin resistance + progressive beta-cell dysfunction |
| UK prevalence | ~400,000 people (~8% of diabetes) | ~4.7 million people (~92% of diabetes) |
| Typical onset | Childhood or young adulthood (can occur at any age) | Middle age (increasingly in younger adults) |
| Treatment cornerstone | Insulin therapy (mandatory) | Lifestyle + oral/injectable medications (insulin if advanced) |
| Key biomarkers | C-peptide (low/absent), autoantibodies (GAD, IA-2, ZnT8) | HbA1c, HOMA-IR, fasting glucose, lipid profile |
| Complications focus | Retinopathy, nephropathy, DKA, hypoglycaemia | Cardiovascular disease, nephropathy, NAFLD, obesity |
Clinical Trial Availability
| Trial Aspect | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| UK trials actively recruiting | 40–70 studies | 120–200 studies |
| Most common trial phase | Phase 1–2 (cure-focused), Phase 3 (tech) | Phase 2–3 (drug), Phase 4 (real-world) |
| Top interventions tested | Immunotherapy, stem cell islets, closed-loop systems, beta-cell regeneration | GLP-1/GIP dual agonists, SGLT2 combos, triple agonists, once-weekly insulins |
| Cure-focused trials | Yes — stem cells, immune tolerance, encapsulation | No — focused on management and complications |
| Technology/device trials | Major category (artificial pancreas, CGMs, pumps) | Growing (CGMs, smart pens, digital health) |
| Prevention trials | Yes (screening at-risk relatives) | Yes (prediabetes, obesity prevention) |
Exciting Emerging Treatments
Type 1 Diabetes Trials
- Stem cell-derived islet transplantation — Vertex VX-880 programme showing insulin independence in early trials
- Teplizumab (anti-CD3) — delays onset by ~2 years in at-risk individuals (FDA-approved, UK trials continuing)
- Closed-loop / artificial pancreas — next-generation hybrid and fully automated systems
- Beta-cell regeneration — therapies to stimulate remaining beta cells to replicate
- Immune tolerance vaccines — antigen-specific approaches to halt autoimmune attack
- Encapsulated islet cells — protecting transplanted cells from immune rejection without immunosuppression
Type 2 Diabetes Trials
- GLP-1/GIP/glucagon triple agonists (retatrutide) — unprecedented HbA1c and weight reductions
- Once-weekly insulins (icodec, efsitora) — reducing injection burden from daily to weekly
- Oral GLP-1 receptor agonists — avoiding injections entirely
- SGLT2 + GLP-1 combination pills — dual mechanism in a single tablet
- Glucose-responsive insulin — "smart insulin" that activates only when blood sugar rises
- AI-driven dosing algorithms — personalised insulin and medication titration
💡 Recently diagnosed with type 1? You may qualify for preservation trials
If you were diagnosed with type 1 diabetes in the last 6 months, you still have some remaining beta cells. Several UK trials are testing therapies to preserve those cells and slow disease progression. The honeymoon period is the best window for these interventions — ask your diabetes team about research opportunities.
Eligibility Differences
Type 1 Diabetes Trial Criteria
- Confirmed autoantibody positivity (GAD, IA-2, ZnT8) usually required for immune intervention trials
- C-peptide level determines residual beta-cell function (key for preservation trials)
- Duration of diabetes matters — newly diagnosed (<6 months) for preservation, any duration for technology trials
- HbA1c thresholds typically 7–10% depending on the intervention
- DKA history may be required (or excluded) depending on trial design
Type 2 Diabetes Trial Criteria
- HbA1c range specified (typically 7–10% for drug trials, may be lower for prevention)
- BMI criteria common — many trials target overweight/obese populations
- Cardiovascular risk profile may determine eligibility for outcomes trials
- Current medication washout may be required (especially for monotherapy trials)
- Renal function thresholds (eGFR) determine eligibility for kidney-related outcome trials
💉 Type 1 Diabetes Trials
Find actively recruiting type 1 diabetes clinical trials across the UK
View Type 1 Trials🩸 Type 2 Diabetes Trials
Find actively recruiting type 2 diabetes clinical trials across the UK
View Type 2 Trials